Pediatrics

Gastroenterology Pediatrics Event Business TASECTAN® TASECTAN® DUO XILAPLUS® / XILAPLUS® AF

ESPGHAN 2023

Noventure will attend the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), taking place in Vienna & Online, from May 17th to 23rd, 2023 Arrange a meeting with us to learn more about our products and license availability in the different countries. Meet us at our Stand #33! Contact us: https://noventure.com/contact-us

Gastroenterology Pediatrics News XILAPLUS® / XILAPLUS® AF

Launch of TASECTAN® AF in Finland and Sweden

Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets. TASECTAN® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children. TASECTAN® AF is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL). For more information about our products click here: http://noventure.com/products

Gastroenterology Pediatrics News XILAPLUS® / XILAPLUS® AF

Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys

Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants.